101.3 million people in one of Asia's fastest-growing economies, a major hepatocellular carcinoma and hepatitis research burden, OUCRU's Oxford-anchored tropical medicine platform, antimicrobial resistance capability, and per-patient costs competitive with any Asian market.
Vietnam is a Socialist Republic of approximately 101.3 million people; ASEAN's third-largest population; stretching approximately 1,650 km north to south along the eastern Indochina Peninsula in an S-shaped configuration that encompasses the Red River Delta and northern highlands, the long central coastline, and the Mekong River Delta in the south. Vietnam shares borders with China to the north, Laos to the northwest, and Cambodia to the southwest, and has been one of Asia's most consistently fast-growing economies over the past three decades; sustaining GDP growth rates of 6–8% per year that have driven rapid urbanisation, healthcare investment, and a growing biomedical research infrastructure. Hanoi, the capital, anchors the northern research corridor through Bach Mai Hospital; northern Vietnam's largest and most prestigious general hospital; the National Hospital for Tropical Diseases (an OUCRU research partner), and Hanoi Medical University. Ho Chi Minh City (HCMC), Vietnam's largest city with approximately 9–10 million people and an extended metro catchment of over 20 million, anchors the southern research corridor through Cho Ray Hospital (southern Vietnam's largest), the Hospital for Tropical Diseases (headquarters of the Oxford University Clinical Research Unit Vietnam), the University Medical Centre HCMC, and the Oncology Hospital (Bệnh viện Ung Bướu). Hue and Da Nang bridge the central Vietnamese corridor, and Can Tho in the Mekong Delta provides access to Vietnam's most dengue-endemic southern populations. Vietnam upgraded its relationship with the United States to a Comprehensive Strategic Partnership in 2023; a diplomatic development with direct implications for bilateral health research collaboration and regulatory alignment with Western pharmaceutical standards.
Clinical trials in Vietnam are regulated by the Drug Administration of Vietnam (DAV / Cục Quản lý Dược) under the Ministry of Health, with clinical trial authorisation governed by Circular 29/2018/TT-BYT and subsequent amendments; a regulatory framework aligned with WHO GCP guidelines and increasingly convergent with ICH technical standards. Ethics review is conducted by institutional ethics committees at research hospitals, with national-level coordination provided by the National Council of Medical Research Ethics (Hội đồng Đạo đức trong Nghiên cứu Y sinh học Quốc gia). Vietnam's universal health insurance system; BHYT (Bảo hiểm Y tế), managed through BHXH Vietnam; has enrolled approximately 92% of the population, creating structured patient care pathways through the public hospital network that provide sponsors with a nationally coherent patient access infrastructure. The Ministry of Health's ongoing investment in clinical research facility upgrading at major hospitals; alongside the OUCRU Wellcome-funded research partnership that has operated in Vietnam for over three decades; has created a clinical trial capability at leading Vietnamese institutions that increasingly meets international sponsor expectations for data quality, protocol compliance, and investigator training depth.
Vietnam's population is approximately 86% Kinh; the dominant Vietnamese ethnic group; with 53 recognised ethnic minorities including the Tày, Thái, Mường, Khmer (Cambodian-origin communities in the Mekong Delta), Hmong, Nùng, Dao, and Gia Rai among the most populous, concentrated in the northern highlands and central plateau regions. The Kinh population has a genetically distinct profile from Han Chinese, Japanese, or Korean populations that is clinically significant for pharmacogenomics: the frequency of CYP2C19 poor metaboliser alleles is substantially higher in Vietnamese populations (~14–20% poor metabolisers) than in European populations (~2–3%); affecting pharmacokinetics of drugs including clopidogrel, proton pump inhibitors, several antidepressants, and antifungals, and making Vietnamese pharmacokinetic data distinct from East Asian and European comparators within global drug development programmes. The national median age is approximately 32 years; young, reflecting Vietnam's demographic dividend and providing deep enrollment breadth across mid-life chronic disease therapeutic areas. English proficiency at academic medical centres in Hanoi and HCMC is good to strong for investigators and senior clinical research professionals; particularly at OUCRU-partnered and internationally connected institutions; while patient-facing materials require Vietnamese-language adaptation. BHYT universal coverage creates the structured hospital-to-patient referral pathway that supports treatment-naïve patient identification across the public hospital network.
Vietnam's disease burden is defined by the simultaneous weight of high infectious disease prevalence; particularly hepatitis B and its sequelae, dengue, tuberculosis, and an emerging antimicrobial resistance crisis; alongside rapidly accelerating non-communicable disease. Hepatitis B virus (HBV) is Vietnam's single most consequential disease: an estimated 10–12% of the Vietnamese population (~10 million people) carries chronic HBV infection; among Asia's highest national HBV carrier rates; creating the enormous hepatocellular carcinoma (HCC) burden that defines Vietnam's most distinctive research identity. Vietnam consistently ranks among the countries with the world's highest HCC incidence rates, driven by the HBV pool plus hepatitis C co-infection, aflatoxin exposure, and alcohol; Vietnamese HCC patients often present with earlier-stage disease than in countries with less surveillance, providing Phase II–III trial enrollment at more actionable disease stages. Dengue fever is hyperendemic throughout Vietnam but particularly intense in the Mekong Delta provinces of the south, where the Hospital for Tropical Diseases HCMC and Can Tho General Hospital manage high case volumes year-round. Tuberculosis affects approximately 170,000 Vietnamese annually; a significant burden, though lower than Indonesia or the Philippines; with drug-resistant TB as a growing research priority. Antimicrobial resistance (AMR), particularly for Gram-negative pathogens and drug-resistant enteric fever (typhoid), represents Vietnam's most internationally distinctive infectious disease research niche through OUCRU's landmark work. Cardiovascular disease has become the leading cause of death. Gastric cancer; driven by very high H. pylori prevalence (~70% in some studies); affects Vietnamese at elevated rates relative to global averages.
HBV and HCC; Vietnam as Asia's most concentrated hepatology research platform outside China: Vietnam's approximately 10 million chronic HBV carriers; representing roughly 10–12% of the national population; constitute one of the world's largest HBV-infected populations in any single country outside China, Pakistan, and sub-Saharan Africa, and have created a hepatocellular carcinoma burden whose incidence rate is among Asia's highest. For sponsors developing HCC therapies; whether systemic treatments (TKIs, immune checkpoint inhibitors, antibody-drug conjugates), interventional approaches (TACE adjuvants, ablation combinations), or novel biologics; Vietnam provides treatment-naïve patient volumes that are structurally essential for Phase II–III Asian enrollment. For sponsors developing HBV antivirals targeting surface antigen clearance, cccDNA suppression, or hepatitis D co-infection, Vietnam's ~10 million HBV carriers represent a patient population whose treatment naivety and disease stage diversity surpass what most Asian markets outside China provide. For HBV-to-HCC prevention programs; trials targeting viral suppression to prevent HCC development; Vietnam's population cohort of young-adult HBV carriers provides the longitudinal follow-up potential for prevention trials that are logistically unfeasible in low-prevalence populations. Vietnam is not merely an important hepatology research site in Southeast Asia; it is the most important one, and the only Southeast Asian country where HCC and HBV trial enrollment can be powered to Phase III statistical requirements without multi-country designs.
Vietnam's research case is built on a convergence of factors that no other ASEAN market assembles in the same configuration: a hepatology and liver cancer research platform of global significance driven by one of Asia's highest HBV carrier rates, a three-decade Oxford University clinical research partnership through OUCRU that has made Vietnamese investigators world leaders in tropical infectious disease and antimicrobial resistance science, 101.3 million people in one of Asia's fastest-growing economies, and per-patient costs competitive with any market in the region; all in a country actively investing in its clinical research infrastructure as a stated national development priority.
Drug Administration of Vietnam (DAV) / Ministry of Health with regulatory framework aligned with WHO GCP and convergent with ICH technical guidelines; Circular 29/2018 and subsequent amendments modernising clinical trial authorisation processes; National Council of Medical Research Ethics providing national ethics policy coordination; BHYT universal coverage creating structured patient care pathways; Vietnam; US Comprehensive Strategic Partnership (2023) driving bilateral health research collaboration and regulatory capacity building; Vietnam-EU Free Trade Agreement (EVFTA) accelerating regulatory standards alignment with European frameworks.
Per-patient and operational costs among ASEAN's most competitive; significantly below Thailand and Malaysia, comparable to Philippines and Indonesia; investigator fees, site overhead, and clinical research professional compensation substantially lower than North Asian markets; Vietnamese Dong (VND) highly favourable for USD- and EUR-denominated trial budgets; growing pool of GCP-trained Vietnamese clinical research professionals available at competitive rates; OUCRU-trained investigator community provides research quality above what cost levels alone would suggest; rapid healthcare infrastructure investment continuing to build site quality.
101.3 million people under ~92% BHYT universal coverage with structured referral pathways; among Asia's highest HCC incidence rates; driven by ~10% HBV carrier rate (~10 million carriers); creating Southeast Asia's largest HCC and HBV patient pool; dengue hyperendemic in Mekong Delta enabling high-volume infectious disease enrollment; high gastric cancer rates (H. pylori-driven) for GI oncology programs; distinctive Vietnamese CYP2C19 pharmacogenomic profile relevant to global pharmacokinetic bridging programs; large treatment-naïve cardiovascular and metabolic disease pools; TB and AMR patient pools for antimicrobial development.
OUCRU (Oxford University Clinical Research Unit); a 30+ year Wellcome-funded tropical medicine research partnership operating at Hospital for Tropical Diseases HCMC and National Hospital for Tropical Diseases Hanoi; Bach Mai Hospital as northern Vietnam's premier general hospital; Cho Ray Hospital as southern Vietnam's largest; K Hospital as national cancer anchor; NIMPE as the national parasitology and tropical disease research institute; growing multinational CRO presence in HCMC and Hanoi; Wellcome-funded investigator training creating internationally published research community at leading Vietnamese sites.
Hepatology and liver oncology is Vietnam's most globally significant and internationally distinctive research domain; shaped entirely by the country's extraordinary HBV burden, which has created patient pools for HCC drug development, HBV antiviral trials, and HBV-HCC prevention programs that are available at equivalent Phase III scale in Asia only in China. Vietnamese HCC patients; often presenting with HBV as the confirmed aetiology, at disease stages earlier than in low-surveillance environments, with limited prior systemic treatment; represent exactly the patient profile that generates the cleanest efficacy data for first- and second-line HCC program development. Infectious disease is Vietnam's second defining research pillar, anchored by over three decades of OUCRU scientific leadership: landmark OUCRU trials have defined the global evidence base for dengue management, enteric fever drug resistance (documenting the rise of azithromycin-resistant Salmonella typhi and extensively drug-resistant XDR typhoid), melioidosis treatment, and antimicrobial resistance surveillance across Southeast Asia; making Vietnamese OUCRU-affiliated investigators the most internationally published tropical medicine researchers in the region outside Thailand's MORU. Dengue research in the Mekong Delta, where HCMC's Hospital for Tropical Diseases manages high transmission-season case volumes, provides a complementary tropical disease platform to Thailand's MORU and the Philippines' RITM. Cardiovascular disease; now the leading cause of Vietnamese mortality; and the rapidly rising Type 2 diabetes burden (from a low base but steep trajectory) are the fastest-growing commercial research pillars. Gastric cancer and gastrointestinal oncology benefit from Vietnam's very high H. pylori prevalence (~70% in some regional studies), while cervical cancer, lung cancer, and haematological malignancies each carry growing research significance through the national oncology hospital network.
Vietnam's clinical research geography divides along the Hanoi–Ho Chi Minh City corridor, separated by approximately 1,700 km but linked by frequent 2-hour flights. Hanoi's cluster of large public hospitals; led by Bach Mai, the national cancer hospital (K Hospital), and the National Hospital for Tropical Diseases; anchors the northern research network. HCMC's research ecosystem is shaped by the Hospital for Tropical Diseases (OUCRU's southern headquarters), Cho Ray Hospital's scale, and the growing University Medical Centre HCMC. The Mekong Delta's Can Tho provides the country's most dengue-endemic research catchment, while Hue and Da Nang bridge the central Vietnamese corridor.
| # | Site | City | Notes |
|---|---|---|---|
| 01 | Bach Mai Hospital (Bệnh viện Bạch Mai) | Hanoi | Northern Vietnam's largest and most prestigious general hospital; the national referral anchor for the north; and the primary academic clinical research institution affiliated with Hanoi Medical University; Phase I–IV across oncology, hepatology (HCC and HBV), cardiovascular, respiratory, nephrology, infectious disease, and internal medicine; Bach Mai hosts Vietnam's National Heart Institute (Viện Tim mạch Quốc gia) and the National Respiratory Hospital (Bệnh viện Hô hấp Trung ương), creating specialist research capability within its broader campus; as northern Vietnam's clinical research anchor, Bach Mai provides the largest patient throughput of any Hanoi hospital for Phase II–III commercial enrollment across multiple therapeutic areas. |
| 02 | K Hospital; National Cancer Hospital (Bệnh viện K Trung Ương) | Hanoi | Vietnam's dedicated national cancer hospital and the primary oncology clinical research institution for northern Vietnam; Phase II–IV across solid tumours (liver cancer/HCC, lung cancer, gastric cancer, breast cancer, colorectal cancer) and haematological malignancies; K Hospital's HCC research programme; among the most active in Southeast Asia for hepatocellular carcinoma; reflects Vietnam's extraordinary liver cancer burden, with high-volume patient enrollment capacity for Phase II–III systemic therapy and interventional oncology trials; Hanoi Medical University affiliate and a key node in international oncology cooperative group partnerships in the Indochina subregion. |
| 03 | National Hospital for Tropical Diseases (Bệnh viện Bệnh Nhiệt Đới Trung Ương) | Hanoi | Northern Vietnam's dedicated tropical disease hospital and an Oxford University Clinical Research Unit (OUCRU) research partner; Phase II–IV across dengue, typhoid and enteric fever, melioidosis, Japanese encephalitis, HIV, antimicrobial resistance, and emerging infectious diseases; the OUCRU northern presence has brought Oxford University's Wellcome-funded research infrastructure; international data management, biostatistics support, investigator training, and global publication networks; to Hanoi, creating a northern Vietnamese infectious disease research capability whose publication output and international regulatory acceptance exceeds what its setting might suggest; an essential site for infectious disease and AMR programs requiring northern Vietnamese patient catchment. |
| 04 | 108 Military Central Hospital (Bệnh viện Trung Ương Quân đội 108) | Hanoi | Vietnam's premier military hospital and one of Hanoi's most research-active institutions, combining the patient volume of a large general hospital with the research investment culture of a nationally funded military medical institution; Phase II–IV across oncology (particularly hepatocellular carcinoma and gastrointestinal cancers), cardiovascular, internal medicine, and rehabilitation medicine; Hospital 108's research programme has an established track record in commercial Phase II–III partnerships across oncology and cardiovascular indications, and its affiliation with the Military Medical Academy creates a strong investigator training pipeline distinct from the civilian university hospital system. |
| 05 | Hanoi Medical University Hospital (Bệnh viện Đại học Y Hà Nội) | Hanoi | The teaching hospital of Hanoi Medical University; Vietnam's oldest and most prestigious medical school; providing Phase II–IV research capability across oncology, cardiovascular, endocrinology, gastroenterology, and internal medicine; a growing commercial Phase II–III portfolio across multiple therapeutic areas, reflecting the University's investment in clinical research infrastructure as a complement to its historically strong basic science research tradition; serves as the investigator training base for Hanoi Medical University's clinical research programme, with a faculty that includes many of Vietnam's most internationally published clinical investigators across oncology and internal medicine. |
| 06 | Hospital for Tropical Diseases HCMC (Bệnh viện Bệnh Nhiệt Đới TP.HCM) | HCMC | The southern headquarters of the Oxford University Clinical Research Unit Vietnam (OUCRU); one of the most internationally connected and prolific tropical medicine research institutions in Southeast Asia; and the site where OUCRU's three decades of landmark dengue, enteric fever, melioidosis, and antimicrobial resistance trials have been conducted; Phase I–IV across all major tropical infectious disease indications including dengue (the definitive Southeast Asian dengue Phase II–III site after RITM in the Philippines), typhoid and drug-resistant enteric fever, melioidosis, HIV, and emerging pathogens; OUCRU's Wellcome-funded infrastructure provides international-standard data management, ethics support, and regulatory submission capability that gives this site a research operating environment comparable to European academic research units despite its middle-income context. |
| 07 | Cho Ray Hospital (Bệnh viện Chợ Rẫy) | HCMC | Southern Vietnam's largest general hospital by patient volume; one of the largest hospitals in Southeast Asia, receiving over 5,000 outpatients daily; and the primary non-specialist academic research anchor for HCMC; affiliated with Ho Chi Minh City University of Medicine and Pharmacy; Phase II–IV across oncology (hepatocellular carcinoma, gastric cancer, lung cancer), hepatology, cardiovascular, infectious disease, and internal medicine; Cho Ray's HCC and hepatology research programme benefits from the highest hepatitis B patient throughput in southern Vietnam, creating enrollment velocities for liver cancer trials that are among the highest of any single site in Southeast Asia; an essential partner for sponsors requiring large-volume southern Vietnamese patient enrollment across oncology and hepatology. |
| 08 | University Medical Centre HCMC (Bệnh viện Đại học Y Dược TP.HCM) | HCMC | The primary teaching hospital of Ho Chi Minh City University of Medicine and Pharmacy (UMP) and one of HCMC's most internationally oriented research institutions; Phase II–IV across oncology, hepatology, cardiovascular, endocrinology, and internal medicine; UMC HCMC's active commercial Phase II–III portfolio reflects the University of Medicine and Pharmacy's investment in building a research-active investigator community in southern Vietnam; particularly strong in hepatocellular carcinoma research; where UMP investigators have contributed to international oncology cooperative programmes; and in pharmacokinetic/pharmacodynamic bridging studies that leverage the distinctive Vietnamese CYP2C19 pharmacogenomic profile for global drug development programs. |
| 09 | Oncology Hospital HCMC (Bệnh viện Ung Bướu TP.HCM) | HCMC | Southern Vietnam's dedicated oncology hospital; operating exclusively as a cancer treatment and research centre; and the primary cancer clinical trial site for the Mekong Delta and southern Vietnam catchment; Phase II–IV across solid tumours (HCC, cervical cancer, breast cancer, lung cancer, and gastrointestinal cancers) and haematological malignancies; Vietnam's high HCC incidence is particularly concentrated in southern Vietnam's HBV-endemic population, making Oncology Hospital HCMC one of the most valuable HCC trial sites in Southeast Asia for Phase II–III systemic therapy and targeted oncology programs; active Cancer Trials network participation across multiple international oncology cooperative group programs. |
| 10 | Hue Central Hospital (Bệnh viện Trung Ương Huế) | Hue | Central Vietnam's major academic hospital and the primary research institution for Hue University of Medicine and Pharmacy; Phase II–III across oncology, cardiovascular, hepatology, and internal medicine; serves the central Vietnamese patient population of approximately 10 million across the coastal provinces between Danang and Quang Ngai, providing important geographic patient diversity within multi-site Vietnamese trial designs; the Hue University of Medicine and Pharmacy's research programme has produced internationally published clinical research in hepatology and oncology, reflecting the central Vietnamese population's HBV burden and cancer profile that is broadly similar to but geographically distinct from the Hanoi and HCMC catchments. |
| 11 | Da Nang Hospital (Bệnh viện Đà Nẵng) | Da Nang | Central Vietnam's fastest-growing city hospital and a Phase II–III research site reflecting Da Nang's rapid emergence as Vietnam's third major urban centre; oncology, cardiovascular, and infectious disease trial activity; Da Nang's geographic position; midway between Hanoi and HCMC, with an international airport serving direct flights to Singapore, Bangkok, and regional ASEAN hubs; makes it an operationally convenient central Vietnamese anchor for multi-site designs; serves the Quang Nam-Da Nang-Quang Ngai corridor catchment of approximately 5 million people whose urban growth trajectory is among Vietnam's most rapid, continuously expanding the available patient pool. |
| 12 | Can Tho General Hospital (Bệnh viện Đa Khoa TP. Cần Thơ) | Can Tho | The Mekong Delta's major regional hospital and the primary research anchor for the most dengue-endemic region of Vietnam; Phase II–III across infectious disease (dengue in particular; the Mekong Delta provinces have among Asia's highest year-round dengue transmission intensity), hepatology, cardiovascular, and internal medicine; Can Tho's dengue research partnership with OUCRU and the Hospital for Tropical Diseases HCMC creates a dedicated dengue clinical trial platform in the country's most affected region; serves the Mekong Delta population of approximately 20 million; characterised by significant rural river-delta communities whose disease exposure patterns and healthcare utilisation profiles are distinct from the urban Hanoi and HCMC catchments. |
Northern Vietnam's largest and most prestigious general hospital; the national referral anchor for the north; and the primary academic clinical research institution affiliated with Hanoi Medical University; Phase I–IV across oncology, hepatology (HCC and HBV), cardiovascular, respiratory, nephrology, infectious disease, and internal medicine; Bach Mai hosts Vietnam's National Heart Institute (Viện Tim mạch Quốc gia) and the National Respiratory Hospital (Bệnh viện Hô hấp Trung ương), creating specialist research capability within its broader campus; as northern Vietnam's clinical research anchor, Bach Mai provides the largest patient throughput of any Hanoi hospital for Phase II–III commercial enrollment across multiple therapeutic areas.
Vietnam's dedicated national cancer hospital and the primary oncology clinical research institution for northern Vietnam; Phase II–IV across solid tumours (liver cancer/HCC, lung cancer, gastric cancer, breast cancer, colorectal cancer) and haematological malignancies; K Hospital's HCC research programme; among the most active in Southeast Asia for hepatocellular carcinoma; reflects Vietnam's extraordinary liver cancer burden, with high-volume patient enrollment capacity for Phase II–III systemic therapy and interventional oncology trials; Hanoi Medical University affiliate and a key node in international oncology cooperative group partnerships in the Indochina subregion.
Northern Vietnam's dedicated tropical disease hospital and an Oxford University Clinical Research Unit (OUCRU) research partner; Phase II–IV across dengue, typhoid and enteric fever, melioidosis, Japanese encephalitis, HIV, antimicrobial resistance, and emerging infectious diseases; the OUCRU northern presence has brought Oxford University's Wellcome-funded research infrastructure; international data management, biostatistics support, investigator training, and global publication networks; to Hanoi, creating a northern Vietnamese infectious disease research capability whose publication output and international regulatory acceptance exceeds what its setting might suggest; an essential site for infectious disease and AMR programs requiring northern Vietnamese patient catchment.
Vietnam's premier military hospital and one of Hanoi's most research-active institutions, combining the patient volume of a large general hospital with the research investment culture of a nationally funded military medical institution; Phase II–IV across oncology (particularly hepatocellular carcinoma and gastrointestinal cancers), cardiovascular, internal medicine, and rehabilitation medicine; Hospital 108's research programme has an established track record in commercial Phase II–III partnerships across oncology and cardiovascular indications, and its affiliation with the Military Medical Academy creates a strong investigator training pipeline distinct from the civilian university hospital system.
The teaching hospital of Hanoi Medical University; Vietnam's oldest and most prestigious medical school; providing Phase II–IV research capability across oncology, cardiovascular, endocrinology, gastroenterology, and internal medicine; a growing commercial Phase II–III portfolio across multiple therapeutic areas, reflecting the University's investment in clinical research infrastructure as a complement to its historically strong basic science research tradition; serves as the investigator training base for Hanoi Medical University's clinical research programme, with a faculty that includes many of Vietnam's most internationally published clinical investigators across oncology and internal medicine.
The southern headquarters of the Oxford University Clinical Research Unit Vietnam (OUCRU); one of the most internationally connected and prolific tropical medicine research institutions in Southeast Asia; and the site where OUCRU's three decades of landmark dengue, enteric fever, melioidosis, and antimicrobial resistance trials have been conducted; Phase I–IV across all major tropical infectious disease indications including dengue (the definitive Southeast Asian dengue Phase II–III site after RITM in the Philippines), typhoid and drug-resistant enteric fever, melioidosis, HIV, and emerging pathogens; OUCRU's Wellcome-funded infrastructure provides international-standard data management, ethics support, and regulatory submission capability that gives this site a research operating environment comparable to European academic research units despite its middle-income context.
Southern Vietnam's largest general hospital by patient volume; one of the largest hospitals in Southeast Asia, receiving over 5,000 outpatients daily; and the primary non-specialist academic research anchor for HCMC; affiliated with Ho Chi Minh City University of Medicine and Pharmacy; Phase II–IV across oncology (hepatocellular carcinoma, gastric cancer, lung cancer), hepatology, cardiovascular, infectious disease, and internal medicine; Cho Ray's HCC and hepatology research programme benefits from the highest hepatitis B patient throughput in southern Vietnam, creating enrollment velocities for liver cancer trials that are among the highest of any single site in Southeast Asia; an essential partner for sponsors requiring large-volume southern Vietnamese patient enrollment across oncology and hepatology.
The primary teaching hospital of Ho Chi Minh City University of Medicine and Pharmacy (UMP) and one of HCMC's most internationally oriented research institutions; Phase II–IV across oncology, hepatology, cardiovascular, endocrinology, and internal medicine; UMC HCMC's active commercial Phase II–III portfolio reflects the University of Medicine and Pharmacy's investment in building a research-active investigator community in southern Vietnam; particularly strong in hepatocellular carcinoma research; where UMP investigators have contributed to international oncology cooperative programmes; and in pharmacokinetic/pharmacodynamic bridging studies that leverage the distinctive Vietnamese CYP2C19 pharmacogenomic profile for global drug development programs.
Southern Vietnam's dedicated oncology hospital; operating exclusively as a cancer treatment and research centre; and the primary cancer clinical trial site for the Mekong Delta and southern Vietnam catchment; Phase II–IV across solid tumours (HCC, cervical cancer, breast cancer, lung cancer, and gastrointestinal cancers) and haematological malignancies; Vietnam's high HCC incidence is particularly concentrated in southern Vietnam's HBV-endemic population, making Oncology Hospital HCMC one of the most valuable HCC trial sites in Southeast Asia for Phase II–III systemic therapy and targeted oncology programs; active Cancer Trials network participation across multiple international oncology cooperative group programs.
Central Vietnam's major academic hospital and the primary research institution for Hue University of Medicine and Pharmacy; Phase II–III across oncology, cardiovascular, hepatology, and internal medicine; serves the central Vietnamese patient population of approximately 10 million across the coastal provinces between Danang and Quang Ngai, providing important geographic patient diversity within multi-site Vietnamese trial designs; the Hue University of Medicine and Pharmacy's research programme has produced internationally published clinical research in hepatology and oncology, reflecting the central Vietnamese population's HBV burden and cancer profile that is broadly similar to but geographically distinct from the Hanoi and HCMC catchments.
Central Vietnam's fastest-growing city hospital and a Phase II–III research site reflecting Da Nang's rapid emergence as Vietnam's third major urban centre; oncology, cardiovascular, and infectious disease trial activity; Da Nang's geographic position; midway between Hanoi and HCMC, with an international airport serving direct flights to Singapore, Bangkok, and regional ASEAN hubs; makes it an operationally convenient central Vietnamese anchor for multi-site designs; serves the Quang Nam-Da Nang-Quang Ngai corridor catchment of approximately 5 million people whose urban growth trajectory is among Vietnam's most rapid, continuously expanding the available patient pool.
The Mekong Delta's major regional hospital and the primary research anchor for the most dengue-endemic region of Vietnam; Phase II–III across infectious disease (dengue in particular; the Mekong Delta provinces have among Asia's highest year-round dengue transmission intensity), hepatology, cardiovascular, and internal medicine; Can Tho's dengue research partnership with OUCRU and the Hospital for Tropical Diseases HCMC creates a dedicated dengue clinical trial platform in the country's most affected region; serves the Mekong Delta population of approximately 20 million; characterised by significant rural river-delta communities whose disease exposure patterns and healthcare utilisation profiles are distinct from the urban Hanoi and HCMC catchments.
These are the primary regulatory, academic, and industry bodies shaping Vietnam's clinical research ecosystem.
Vietnam's pharmaceutical regulatory authority under the Ministry of Health, responsible for clinical trial authorisation under Circular 29/2018/TT-BYT and subsequent amendments; regulatory standards aligned with WHO GCP guidelines and increasingly convergent with ICH technical guidance; all clinical trial applications assessed in Vietnamese with English-language protocol summaries accepted; DAV's ongoing regulatory modernisation; including digital submission systems and expedited review tracks; has been progressively reducing authorisation timelines; the Vietnam; US Comprehensive Strategic Partnership (2023) has initiated regulatory capacity-building collaboration that is accelerating DAV's alignment with FDA-compatible review frameworks.
The overarching national health authority governing clinical trial policy, hospital research authorisation, and the National Council of Medical Research Ethics (NCMER) that coordinates institutional ethics committee standards across Vietnamese research hospitals; the Ministry's Health Research and Training Department manages the national clinical research development strategy, including investment in clinical research facility upgrades at priority public hospitals; the Ministry's BHYT universal health insurance mandate; having enrolled approximately 92% of the population; creates the patient care pathway infrastructure that underpins commercial trial enrollment at all Ministry-affiliated hospital sites.
Vietnam's dedicated national parasitology and vector-borne disease research institution, operating under the Ministry of Health; maintains Vietnam's national malaria and parasitic disease surveillance system and conducts clinical research in malaria, dengue, helminthiases, and neglected tropical diseases; a key research partner for sponsors developing antimalarial therapies or insecticide-treated intervention programs requiring Vietnamese patient populations in the central highlands and border regions where remnant malaria transmission persists; NIMPE's national surveillance data provides epidemiological feasibility information for infectious disease trial planning across all Vietnamese provinces.
One of Asia's most productive and internationally recognised tropical medicine research institutions; a Wellcome Trust–funded collaboration between Oxford University and the Vietnamese Ministry of Health, operating for over three decades at the Hospital for Tropical Diseases HCMC and the National Hospital for Tropical Diseases Hanoi; has produced landmark clinical evidence in dengue (fluid management, pharmacokinetics), enteric fever (drug resistance trajectories, XDR typhoid emergence), melioidosis, sepsis, and antimicrobial resistance; output that has directly shaped WHO clinical management guidelines; provides international-standard data management, biostatistics, ethics support, and regulatory submission capability to OUCRU-partnered trials; the most important single institutional asset in Vietnamese clinical research and the primary reason Vietnamese infectious disease investigators hold world-class standing.
Vietnam's oldest and most prestigious medical school, affiliated with Bach Mai Hospital, K Hospital, and other major Hanoi research institutions; produces the largest volume of internationally published Vietnamese clinical research output across oncology, hepatology, cardiovascular medicine, and infectious disease; its faculty includes many of Vietnam's most senior and internationally connected clinical investigators; the Hanoi Medical University research training programme, including a growing number of internationally co-supervised PhD graduates, is continuously building the next generation of GCP-trained Vietnamese investigators available for commercial Phase II–III partner programs.
Southern Vietnam's premier medical university, affiliated with the University Medical Centre HCMC, Cho Ray Hospital, and Oncology Hospital HCMC; a research-active institution with particular strength in hepatology, oncology, pharmacology, and clinical pharmacokinetics; UMP's pharmacology department has been active in pharmacokinetic bridging studies leveraging the Vietnamese CYP2C19 poor metaboliser frequency for global drug development programs; international collaborative research partnerships with Australian, Japanese, and US academic institutions have built an internationally oriented research culture at UMP that increasingly attracts commercial sponsor partnership interest.
Global CRO with Vietnamese operations managing Phase II–IV programs across hepatology (HCC and HBV), oncology, cardiovascular, and infectious disease indications; DAV regulatory submission expertise and national ethics committee application support; established site monitoring presence at Bach Mai Hospital, K Hospital, Hospital for Tropical Diseases HCMC, Cho Ray Hospital, and University Medical Centre HCMC; real-world data and pharmacovigilance capability drawing on BHYT administrative data; ASEAN regional trial network coordination from the HCMC and Hanoi offices spanning Vietnam, Thailand, and Malaysia within integrated Southeast Asian Phase III programs.
International CRO with Vietnamese operations supporting Phase II–IV hepatology, oncology, infectious disease, and cardiovascular programs; specialist HCC and HBV clinical trial management experience reflecting Vietnam's hepatology research profile; established investigator relationships at Hospital for Tropical Diseases HCMC (OUCRU partner), Bach Mai Hospital, K Hospital, and Cho Ray Hospital; DAV regulatory strategy for sponsors using Vietnam as a primary Asian hepatology anchor or as a cost-optimising secondary site within pan-Asian Phase III hepatocellular carcinoma and HBV programs.
Global CRO with Vietnamese operations providing Phase II–III trial management and regulatory strategy across oncology, hepatology, cardiovascular, and infectious disease; established site networks across Hanoi and HCMC academic hospital clusters; DAV submission and ethics committee application support; supports sponsors designing pan-ASEAN trial networks that position Vietnam as the HCC and hepatology anchor alongside Thai and Malaysian sites within broader Asia-Pacific programs; biostatistics and data management for Vietnamese-site trials with pharmacogenomic sub-group analysis for CYP2C19 and other Vietnamese-relevant variant frequencies.
International biopharmaceutical solutions company with Vietnamese operations providing integrated clinical development and commercialisation services across Phase I–IV; specialist capability in biologics, oncology (particularly HCC and gastrointestinal cancers), and infectious disease programs leveraging Vietnam's disease profile; operational presence in both HCMC and Hanoi enabling dual-corridor trial management across the Vietnamese research geography; growing Vietnamese regulatory strategy capability supporting sponsors seeking DAV submissions for oncology, hepatology, and infectious disease indications as Vietnam's commercial pharmaceutical market expands with GDP growth.
Vietnam is Southeast Asia's most rapidly ascending clinical research market and the region's single most important destination for hepatology and liver oncology programs. The HBV/HCC argument is the editorial spine of Vietnam's research identity; approximately 10 million chronic HBV carriers in a 101-million population, and hepatocellular carcinoma incidence rates among the world's highest, create a liver cancer and HBV antiviral research platform available at Phase III-powerable scale in Southeast Asia only in Vietnam. For sponsors developing HCC therapies, HBV antivirals, or HBV-to-HCC prevention strategies, Vietnamese sites provide the patient volumes, treatment-naïve disease stages, and HBV-aetiology confirmation that make them structurally essential rather than merely attractive. OUCRU; the Oxford University Clinical Research Unit that has operated in Vietnam for over three decades with Wellcome Trust funding; provides the second editorial pillar: a tropical infectious disease research institution whose publication record, WHO guideline contributions, and international regulatory acceptance elevate the entire Vietnamese clinical trial ecosystem beyond what GDP or market size would predict. OUCRU's landmark work in dengue, drug-resistant typhoid, and antimicrobial resistance has made Vietnamese investigators the most internationally respected tropical medicine clinical researchers in the Indochina subregion. 101 million people under 92% BHYT health coverage provide the patient access architecture. Costs competitive with any ASEAN market provide the financial rationale. A Vietnam; US Comprehensive Strategic Partnership and Vietnam; EU Free Trade Agreement provide the regulatory convergence momentum. Vietnam is not yet as operationally streamlined as Thailand or Malaysia, but for sponsors whose programs are hepatology-anchored, infectious-disease-defined, or seeking a high-quality, high-value addition to an existing Asian trial network, it has no regional substitute.
Keep exploring
Discover 11 early-phase clinical trials and design frameworks redefining development strategy in 2025-2026, and what sponsors can learn to reduce late-stage failure risk.
Four pervasive AI misconceptions in clinical trials that derail programs, inflate costs, and create regulatory exposure, with evidence on what the data actually shows.
Before selecting an AI patient screening tool for clinical trial recruitment, ask these 7 critical questions to avoid costly mismatches and protocol failures.
Accelerated Approval is an FDA pathway that allows earlier approval of drugs treating serious conditions and filling unmet medical need on the basis of a surrogate endpoint that is reasonably likely to predict clinical benefit, conditional on confirmatory post-marketing trials.